Also known as: Arpeggio Biosciences
Arpeggio Bio develops drugs targeting transcription factors using AI…
Company is active
Event Year: 2019
Company is active
Event Year: 2019
Arpeggio Bio is an innovative pharmaceutical company focused on creating novel therapeutics that target transcription factors. The company leverages the power of artificial intelligence and high-throughput RNA sequencing to develop these drugs. Having secured $20 million in venture capital, Arpeggio Bio is concentrating on previously "undruggable" proteins such as NRF2, TEAD, and GPX4. Their primary program is advancing swiftly towards a data cut-off (DC) for treating melanoma that is resistant to immuno-oncology therapies. Furthermore, strategic partnerships with industry leaders like Johnson & Johnson and FORMA Therapeutics have validated Arpeggio Bio's platform in the areas of rare diseases and inflammation, marked by notable success in Phase I clinical trials.
Arpeggio Bio is an innovative pharmaceutical company focused on creating novel therapeutics that target transcription factors. The company leverages the power of artificial intelligence and high-throughput RNA sequencing to develop these drugs. Having secured $20 million in venture capital, Arpeggio Bio is concentrating on previously "undruggable" proteins such as NRF2, TEAD, and GPX4. Their primary program is advancing swiftly towards a data cut-off (DC) for treating melanoma that is resistant to immuno-oncology therapies. Furthermore, strategic partnerships with industry leaders like Johnson & Johnson and FORMA Therapeutics have validated Arpeggio Bio's platform in the areas of rare diseases and inflammation, marked by notable success in Phase I clinical trials.
Total Raised: Unknown (Y Combinator backed)
Last Round: Summer 2019
Total Raised: Unknown (Y Combinator backed)
Last Round: Summer 2019
Healthcare
Healthcare
Healthcare -> Drug Discovery and Delivery
Healthcare -> Drug Discovery and Delivery
Team size: 20
Hiring: No
Team size: 20
Hiring: No
